Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease.
CONCLUSIONS: Administration of oral or IV/oral ademetionine step-therapy for 8 weeks to subjects with IHC due to ALD was safe and provided a significant improvement of disease burden.
PMID: 29431335 [PubMed - as supplied by publisher]
Source: Minerva Gastroenterologica e Dietologica - Category: Gastroenterology Tags: Minerva Gastroenterol Dietol Source Type: research
More News: Alcoholism | Bilirubin | Cholestasis | Gastroenterology | Laboratory Medicine | Liver | Liver Disease | Nutrition | Obstetric Cholestasis | Study | Urology & Nephrology